← back to search

Bernard Moss

The University of Texas Health Science Center at San Antonio · US
Area of research
Virology · Genetics
Research interest
Research interests include Poxvirus research and outbreaks, Virus-based gene therapy research, Herpesvirus Infections and Treatments, and Bacteriophages and microbial interactions.
h-index
152
citations
81,681
works
976
NIH funding
primary concept
email

Recent publications

Poxvirus structural biology for application to vaccine design
Trends in Immunology 2025cited by 9position: lastdoi
A functional approach to analyze the genetic basis for differences in virulence of monkeypox virus clades.
2025cited by 4position: contributordoi
Mpox multiprotein virus-like nanoparticle vaccine induces neutralizing and protective antibodies in mice and non-human primates.
2025cited by 4position: contributordoi
Antibody Binding and Neutralizing Targets within the Predicted Structure of the Poxvirus Multiprotein Entry-Fusion Complex
2025cited by 2position: lastdoi
Identification and characterization of O-GlcNAc modifications of a conserved orthopoxvirus core protein.
2025cited by 0position: contributordoi
The 2.3 Å Structure of A21, a Protein Component of the Conserved Poxvirus Entry-Fusion Complex
2025cited by 0position: middledoi
Understanding the biology of monkeypox virus to prevent future outbreaks.
2024cited by 49position: contributordoi
Comparison of the immunogenicity and protective efficacy of ACAM2000, MVA, and vectored subunit vaccines for Mpox in rhesus macaques.
2024cited by 28position: contributordoi
Mpox mRNA-1769 vaccine inhibits orthopoxvirus replication at intranasal, intrarectal, and cutaneous sites of inoculation.
2024cited by 12position: contributordoi
Virulence differences of mpox (monkeypox) virus clades I, IIa, and IIb.1 in a small animal model.
2023cited by 147position: contributordoi
An mpox virus mRNA-lipid nanoparticle vaccine confers protection against lethal orthopoxviral challenge.
2023cited by 81position: contributordoi
Exaptation of Inactivated Host Enzymes for Structural Roles in Orthopoxviruses and Novel Folds of Virus Proteins Revealed by Protein Structure Modeling
mBio 2023cited by 26position: lastdoi
Human FAM111A inhibits vaccinia virus replication by degrading viral protein I3 and is antagonized by poxvirus host range factor SPI-1.
2023cited by 20position: contributordoi
Protection from SARS-CoV-2 Variants by MVAs expressing matched or mismatched S administered intranasally to mice.
2023cited by 4position: contributordoi
Intranasal inoculation of an MVA-based vaccine induces IgA and protects the respiratory tract of hACE2 mice from SARS-CoV-2 infection.
2022cited by 55position: contributordoi
Exaptation of inactivated host enzymes for structural roles in orthopoxviruses and novel protein folds revealed by protein structure modeling
2022cited by 2position: lastdoi
Interferon α/β Decoy Receptor Encoded by a Variant in the Dryvax Smallpox Vaccine Contributes to Virulence and Correlates with Severe Vaccine Side Effects.
2022cited by 2position: contributordoi
Virulence Differences of Monkeypox Virus Clades 1, 2a and 2b.1 in a Small Animal Model
2022cited by 0position: contributordoi
Enhanced Protection from SARS-CoV-2 Variants by MVA-Based Vaccines Expressing Matched or Mismatched S Proteins Administered Intranasally to hACE2 Mice
2022cited by 0position: contributordoi
Ancient Gene Capture and Recent Gene Loss Shape the Evolution of Orthopoxvirus-Host Interaction Genes
mBio 2021cited by 134position: lastdoi
One or two injections of MVA-vectored vaccine shields hACE2 transgenic mice from SARS-CoV-2 upper and lower respiratory tract infection.
2021cited by 63position: contributordoi
Insights into the Organization of the Poxvirus Multicomponent Entry-Fusion Complex from Proximity Analyses in Living Infected Cells.
2021cited by 20position: contributordoi
MVA Vector Vaccines Inhibit SARS CoV-2 Replication in Upper and Lower Respiratory Tracts of Transgenic Mice and Prevent Lethal Disease
2021cited by 8position: lastdoi
Spontaneous and Targeted Mutations in the Decapping Enzyme Enhance Replication of Modified Vaccinia Virus Ankara (MVA) in Monkey Cells.
2021cited by 5position: contributordoi
Research with variola virus after smallpox eradication: Development of a mouse model for variola virus infection.
2021cited by 4position: contributordoi
Loss of the vaccinia virus 35-amino acid hydrophobic O3 protein is partially compensated by mutations in the transmembrane domains of other entry proteins.
2021cited by 4position: contributordoi
Natural killer cells expanded in vivo or ex vivo with IL-15 overcomes the inherent susceptibility of CAST mice to lethal infection with orthopoxviruses.
2020cited by 47position: contributordoi
Zinc-finger antiviral protein (ZAP) is a restriction factor for replication of modified vaccinia virus Ankara (MVA) in human cells.
2020cited by 38position: contributordoi
Repair of a previously uncharacterized second host-range gene contributes to full replication of modified vaccinia virus Ankara (MVA) in human cells.
2020cited by 30position: contributordoi
Inactivation of Genes by Frameshift Mutations Provides Rapid Adaptation of an Attenuated Vaccinia Virus.
2020cited by 17position: contributordoi

Grants

No grants ingested yet.

Frequent collaborators

Catherine A. Cotter · National Institute of Allergy and Infectious Diseases4 papers (2021–2024) · 3 papers (2021–2023)Eugene V. Koonin · United States National Library of Medicine3 papers (2021–2023)Chen Peng · China Agricultural University3 papers (2020–2023)Dan H. Barouch · Ragon Institute of MGH, MIT and Harvard2 papers (2019–2024)Darren Ty · Beth Israel Deaconess Medical Center1 papers (2024–2024)David N. Garboczi · National Institutes of Health1 papers (2025–2025)Liya A. Muslinkina · National Institutes of Health1 papers (2025–2025)Geoffrey L. Smith · The Pirbright Institute1 papers (2021–2021) · 1 papers (2024–2024)Ruth Hunegnaw · National Institutes of Health1 papers (2023–2023)Tiffany R. Frey · Moderna Therapeutics (United States)1 papers (2023–2023)Jay W. Hooper · United States Army Medical Research Institute of Infectious Diseases1 papers (2023–2023)Eric M. Mucker · United States Army Medical Research Institute of Infectious Diseases1 papers (2024–2024)Alec W. Freyn · Rochester Institute of Technology1 papers (2023–2023)Shira Glushakow-Smith · National Institute of Allergy and Infectious Diseases1 papers (2020–2020)Rama R. Amara · Oregon National Primate Research Center1 papers (2019–2019)Patricia A. Jorquera · Moderna Therapeutics (United States)1 papers (2023–2023)Jason G. Gall · University of Bamako1 papers (2023–2023)Apostolos G. Gittis · National Institutes of Health1 papers (2025–2025)